On August 20, McDonald’s announced that it will lower the cost of its popular combo meals in the US as part of an effort to ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).